Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Mesenchymal Stem Cells and Myeloid Derived Suppressor Cells: Common Traits in Immune Regulation.

Vladimirovna IL, Sosunova E, Nikolaev A, Nenasheva T.

J Immunol Res. 2016;2016:7121580. doi: 10.1155/2016/7121580. Epub 2016 Jul 27. Review.

2.

Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine.

Najac C, Chaumeil MM, Kohanbash G, Guglielmetti C, Gordon JW, Okada H, Ronen SM.

Sci Rep. 2016 Aug 10;6:31397. doi: 10.1038/srep31397.

3.

Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Buqué A, Bloy N, Aranda F, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2016 Mar 10;5(6):e1149674. doi: 10.1080/2162402X.2016.1149674. eCollection 2016 Jun. Review.

PMID:
27471617
4.

Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy.

Hou W, Sampath P, Rojas JJ, Thorne SH.

Cancer Cell. 2016 Jul 11;30(1):108-19. doi: 10.1016/j.ccell.2016.05.012. Epub 2016 Jun 30.

PMID:
27374223
5.

Boswellic acid activity against glioblastoma stem-like cells.

Schneider H, Weller M.

Oncol Lett. 2016 Jun;11(6):4187-4192. Epub 2016 May 4.

6.

Doxorubicin resistant cancer cells activate myeloid-derived suppressor cells by releasing PGE2.

Rong Y, Yuan CH, Qu Z, Zhou H, Guan Q, Yang N, Leng XH, Bu L, Wu K, Wang FB.

Sci Rep. 2016 Apr 1;6:23824. doi: 10.1038/srep23824.

7.

CXCL10 and CCL2 mRNA expression in monocytes is inversely correlated with the HLA-DR lower fraction of monocytes in patients with renal cell carcinoma.

Motoshima T, Komohara Y, Horlad H, Tsukamoto H, Fujita M, Saito Y, Tanoue K, Kasejima Y, Sugiyama Y, Kawano Y, Nishimura Y, Takeya M, Eto M.

Oncol Lett. 2016 Mar;11(3):1911-1916. Epub 2016 Jan 20.

8.

Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype.

Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, Thomas G, Zhou S, Wang Q, Elakkad A, Liebelt BD, Yaghi NK, Ezhilarasan R, Huang N, Weinberg JS, Prabhu SS, Rao G, Sawaya R, Langford LA, Bruner JM, Fuller GN, Bar-Or A, Li W, Colen RR, Curran MA, Bhat KP, Antel JP, Cooper LJ, Sulman EP, Heimberger AB.

JCI Insight. 2016;1(2). pii: e85841. Epub 2016 Feb 25.

10.

Use of Selective Cyclooxygenase-2 Inhibitors, Other Analgesics, and Risk of Glioma.

Seliger C, Meier CR, Becker C, Jick SS, Bogdahn U, Hau P, Leitzmann MF.

PLoS One. 2016 Feb 12;11(2):e0149293. doi: 10.1371/journal.pone.0149293. eCollection 2016.

11.

Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent.

Pantziarka P, Sukhatme V, Bouche G, Meheus L, Sukhatme VP.

Ecancermedicalscience. 2016 Jan 11;10:610. doi: 10.3332/ecancer.2016.610. eCollection 2016.

12.

Synergistic COX2 Induction by IFNγ and TNFα Self-Limits Type-1 Immunity in the Human Tumor Microenvironment.

Wong JL, Obermajer N, Odunsi K, Edwards RP, Kalinski P.

Cancer Immunol Res. 2016 Apr;4(4):303-11. doi: 10.1158/2326-6066.CIR-15-0157. Epub 2016 Jan 27.

PMID:
26817996
13.

Activated hepatic stellate cells promote liver cancer by induction of myeloid-derived suppressor cells through cyclooxygenase-2.

Xu Y, Zhao W, Xu J, Li J, Hong Z, Yin Z, Wang X.

Oncotarget. 2016 Feb 23;7(8):8866-78. doi: 10.18632/oncotarget.6839.

14.

Biomedical insights into cell adhesion and migration-from a viewpoint of central nervous system tumor immunology.

Fujita M, Matsui T, Ito A.

Front Cell Dev Biol. 2015 Oct 14;3:55. doi: 10.3389/fcell.2015.00055. eCollection 2015. No abstract available.

15.

Histamine deficiency promotes accumulation of immunosuppressive immature myeloid cells and growth of murine gliomas.

Ahn B, Kohanbash G, Ohkuri T, Kosaka A, Chen X, Ikeura M, Wang TC, Okada H.

Oncoimmunology. 2015 May 26;4(11):e1047581. eCollection 2015 Nov.

16.

COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells.

Li ZL, Ye SB, OuYang LY, Zhang H, Chen YS, He J, Chen QY, Qian CN, Zhang XS, Cui J, Zeng YX, Li J.

Oncoimmunology. 2015 Jul 9;4(11):e1044712. eCollection 2015 Nov.

17.

Transcriptional regulation of myeloid-derived suppressor cells.

Condamine T, Mastio J, Gabrilovich DI.

J Leukoc Biol. 2015 Dec;98(6):913-22. doi: 10.1189/jlb.4RI0515-204R. Epub 2015 Sep 3. Review.

PMID:
26337512
18.

Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites.

Perng P, Lim M.

Front Oncol. 2015 Jul 6;5:153. doi: 10.3389/fonc.2015.00153. eCollection 2015. Review.

19.

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.

Marvel D, Gabrilovich DI.

J Clin Invest. 2015 Sep;125(9):3356-64. doi: 10.1172/JCI80005. Epub 2015 Jul 13. Review.

PMID:
26168215
20.

Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme.

Yang L, Guo G, Niu XY, Liu J.

Biomed Res Int. 2015;2015:717530. doi: 10.1155/2015/717530. Epub 2015 Jun 17. Review.

Items per page

Supplemental Content

Write to the Help Desk